Enanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors
November 25 2013 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Bruce L.A. Carter, Ph.D. to its Board of Directors.
Dr. Carter will also serve as a member of the Compensation and the
Nominating and Corporate Governance Committees. The Board also
announced today the resignation of Helmut M. Schuhsler, Ph.D. as a
director.
“Dr. Carter’s combination of scientific expertise and
operational experience in the healthcare field will be invaluable
to Enanta as we continue to research infectious disease areas and
advance our lead compounds,” stated Jay R. Luly, Ph.D. President
and Chief Executive Officer. “I would also like to thank Helmut for
his leadership, guidance and dedication to Enanta, which we have
benefited from since he first joined our Board in 1998. I wish him
continued success.”
“It is a privilege to join Enanta’s Board at this exciting time
in the company’s history,” commented Bruce L.A. Carter, Ph.D. “I
look forward to my service on the Board and to contributing to the
company’s future success.”
Dr. Carter has extensive experience in the pharmaceutical
industry including positions as an executive and director. He
currently serves as a director of Dr. Reddy’s Ltd., Immune Design
Corp, Xencor Inc. and Regulus Therapeutics and is currently an
Affiliate Professor, Department of Biochemistry at the University
of Washington, Seattle, Washington.
Dr. Carter served as Executive Chairman of Immune Design Corp.
from 2009 to 2011. From 2000 to 2009, he held executive management
positions at ZymoGenetics, Inc., where he served as President and
Chief Executive Officer until 2009, and continued as Chairman of
the Board until 2010, when the company was acquired by Bristol
Myers Squibb. He worked at Novo Nordisk from 1994 to 2000 as
Corporate Executive Vice President and Chief Scientific Officer.
Previously he was at ZymoGenetics, which was acquired by Novo
Nordisk, where he served as their President from 1988 to 1994 and
as Vice President Research and Development from 1986 to 1988. Dr.
Carter began his career at G.D. Searle & Co. Ltd. where from
1982 to 1986 he was Head of Molecular Genetics.
Dr. Carter received a B.Sc. with Honors in Botany from the
University of Nottingham, England, and a Ph.D. in Microbiology from
Queen Elizabeth College, University of London.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
the direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024